McBrien C, OConnell D
BioTech (Basel). 2025; 14(1).
PMID: 39982274
PMC: 11843943.
DOI: 10.3390/biotech14010007.
Qian X, Jin X, He J, Zhang J, Hu S
Oncol Lett. 2024; 29(1):34.
PMID: 39512509
PMC: 11542162.
DOI: 10.3892/ol.2024.14781.
Mavingire N, Moore J, Johnson J, Dwead A, Cropp C, Mechref Y
Cancers (Basel). 2024; 16(19).
PMID: 39409883
PMC: 11476348.
DOI: 10.3390/cancers16193262.
Hayashi H, Mak T, Tanaka Y, Kubo Y, Izumida M, Urae R
Proc Natl Acad Sci U S A. 2024; 121(33):e2318190121.
PMID: 39106307
PMC: 11331103.
DOI: 10.1073/pnas.2318190121.
Cheng X
Genes (Basel). 2024; 15(7).
PMID: 39062682
PMC: 11275319.
DOI: 10.3390/genes15070903.
Impending role of inflammatory markers and their specificity and sensitivity in breast cancer patients.
Malik S, Waquar S, Idrees N, Malik A
Sci Rep. 2024; 14(1):15117.
PMID: 38956273
PMC: 11219843.
DOI: 10.1038/s41598-024-65821-8.
p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway.
Fondevila M, Novoa E, Gonzalez-Rellan M, Fernandez U, Heras V, Porteiro B
Cell Rep Med. 2024; 5(2):101401.
PMID: 38340725
PMC: 10897550.
DOI: 10.1016/j.xcrm.2024.101401.
Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.
Liang K, Feliciano J, Marrone K, Murray J, Hann C, Anagnostou V
ESMO Open. 2023; 9(1):102199.
PMID: 38071928
PMC: 10837776.
DOI: 10.1016/j.esmoop.2023.102199.
Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells.
Shu W, Wang J, Zhu X, Wang K, Cherepanoff S, Conway R
J Cancer. 2023; 14(18):3477-3495.
PMID: 38021158
PMC: 10647189.
DOI: 10.7150/jca.88446.
The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages.
Sun S, Man X, Zhou D, Zheng F, Zhao J, Chen X
Cancer Med. 2023; 12(18):18850-18860.
PMID: 37688399
PMC: 10557883.
DOI: 10.1002/cam4.6509.
BRCA1 and NORE1A Form a Her2/Ras Regulated Tumor Suppressor Complex Modulating Senescence.
Nelson N, Jigo R, Clark G
Cancers (Basel). 2023; 15(16).
PMID: 37627161
PMC: 10452424.
DOI: 10.3390/cancers15164133.
Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population-based study in patients with breast cancer.
Chai Y, Chen Y, Liu J, He M, Jiang M, Xu B
Thorac Cancer. 2023; 14(27):2793-2803.
PMID: 37558505
PMC: 10518231.
DOI: 10.1111/1759-7714.15073.
Risk factors and survival prediction of young breast cancer patients with liver metastases: a population-based study.
Pu C, Yin L, Yan J
Front Endocrinol (Lausanne). 2023; 14:1158759.
PMID: 37424855
PMC: 10328090.
DOI: 10.3389/fendo.2023.1158759.
Molecular Dynamics-Based Design and Biophysical Evaluation of Thermostable Single-Chain Fv Antibody Mutants Derived from Pharmaceutical Antibodies.
Okazaki K, Kobashigawa Y, Morita H, Yamauchi S, Fukuda N, Liu C
ACS Omega. 2023; 8(25):22945-22954.
PMID: 37396255
PMC: 10308585.
DOI: 10.1021/acsomega.3c01948.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S, Xie S, Liu W, Gagea M, Hanker A, Nguyen N
Breast Cancer Res. 2023; 25(1):62.
PMID: 37280713
PMC: 10245436.
DOI: 10.1186/s13058-023-01665-w.
Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D, Zaki K, Beavil A, Arnold J, Diebold S
PLoS One. 2023; 18(3):e0282831.
PMID: 36913398
PMC: 10010539.
DOI: 10.1371/journal.pone.0282831.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S, Xie S, Liu W, Gagea M, Hanker A, Nguyen N
Res Sq. 2023; .
PMID: 36824840
PMC: 9949251.
DOI: 10.21203/rs.3.rs-2388864/v1.
Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study.
Fan J, Zhang S, Yang H, Yi Z, Ouyang Q, Yan M
Front Oncol. 2023; 13:978985.
PMID: 36761968
PMC: 9905808.
DOI: 10.3389/fonc.2023.978985.
Transcriptomic Changes Associated with Overexpression in Colorectal Cancer Implicate a Potential Role of the Wnt Signaling Pathway in Tumorigenesis.
Abdul Razzaq E, Bajbouj K, Bouzid A, Alkhayyal N, Hamoudi R, Bendardaf R
Cancers (Basel). 2023; 15(1).
PMID: 36612126
PMC: 9817785.
DOI: 10.3390/cancers15010130.
Small molecule inhibitors targeting the cancers.
Liu G, Chen T, Zhang X, Ma X, Shi H
MedComm (2020). 2022; 3(4):e181.
PMID: 36254250
PMC: 9560750.
DOI: 10.1002/mco2.181.